DBV Technologies S.A. (DBV.PA)
| Previous Close | 0.9300 |
| Open | 0.9250 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.9210 - 0.9290 |
| 52 Week Range | 0.9100 - 3.5980 |
| Volume | |
| Avg. Volume | 94,094 |
| Market Cap | 92.576M |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7600 |
| Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.76 |
GlobeNewswireDBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Châtillon, France, June 5, 2024 DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45th Annual Goldman Sachs G
- GlobeNewswire
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024
Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights05/31/2024 96,493,078 Total gross of voting rights: 96,493,078 Total net* of voting rights: 96,236,383 * Net total = total number of voting rights attached to shares – shares without voting
- GlobeNewswire
DBV Technologies Announces Plan to Implement ADS Ratio Change
Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value
